Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

被引:65
作者
Harrison, TW
Wisniewski, A
Honour, J
Tattersfield, AE
机构
[1] City Hosp Nottingham, Div Resp Med, Nottingham NG5 1PB, England
[2] UCL Hosp, Dept Chem Pathol, London W1N 8AA, England
关键词
inhaled corticosteroids; asthma; systemic effects;
D O I
10.1136/thorax.56.3.186
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background-The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fluticasone propionate and budesonide have been compared in this way the results have been inconsistent. To determine whether this is because of the subjects studied or the sensitivity of the systemic marker used, we have compared the effects of fluticasone propionate and budesonide in healthy and asthmatic subjects and investigated the effect of treatment on three systemic markers. Methods-Forty six healthy subjects were randomised to receive inhaled fluticasone propionate 1500 mug/day (via an Accuhaler), budesonide 1600 mug/day (via a Turbuhaler), or placebo; 31 subjects with moderately severe asthma were randomised to receive the same doses of fluticasone propionate or budesonide but not placebo. Systemic effects in healthy and asthmatic subjects were compared after 7 days. Treatment was continued for another 21 days in the subjects with asthma when systemic effects and asthma control were assessed. Results-At baseline healthy subjects had higher urinary levels of total cortisol metabolites (TCM) than subjects with asthma. After 7 days of treatment with fluticasone propionate urinary TCM levels in the healthy subjects were significantly lower than in the subjects with asthma (mean difference between groups 1663 mug/day, 95% CI 328 to 2938). This was not the case with budesonide, however, where urinary TCM levels in the healthy subjects remained above those in the asthmatic subjects (mean difference between groups 1210 mug/day, 95% CI -484 to 2904). Urinary TCM levels were considerably more sensitive to the effects of inhaled corticosteroids than morning serum cortisol or osteocalcin concentrations. Only budesonide reduced the serum level of osteocalcin. Conclusions-When given by dry powder inhaler for 7 days, fluticasone propionate 1500 mug/day has a greater effect on the hypothalamic-pituitary-adrenal axis in healthy subjects than in subjects with asthma, but this is not the case for budesonide 1600 mug/day. These findings, together with the differences in sensitivity between systemic markers, explain many of the discrepancies in the literature.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 25 条
[1]
AYRES JG, 1995, EUR RESPIR J, V8, P579
[2]
BARNES NC, 1993, EUR RESPIR J, V6, P877
[3]
Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less [J].
Barnes, NC ;
Hallett, C ;
Harris, TAJ .
RESPIRATORY MEDICINE, 1998, 92 (01) :95-104
[4]
EFFICACY AND SAFETY OF INHALED CORTICOSTEROIDS IN ASTHMA - REPORT OF A WORKSHOP HELD IN EZE, FRANCE, OCTOBER 1992 [J].
BARNES, PJ ;
PEDERSEN, S .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (04) :S1-S26
[5]
Assessment of the relative systemic potency of inhaled fluticasone and budesonide [J].
Boorsma, M ;
Andersson, N ;
Larsson, P ;
Ullman, A .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (07) :1427-1432
[6]
Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study [J].
Brutsche, MH ;
Brutsche, IC ;
Munavvar, M ;
Langley, SJ ;
Masterson, CM ;
Daley-Yates, PT ;
Brown, R ;
Custovic, A ;
Woodcock, A .
LANCET, 2000, 356 (9229) :556-561
[7]
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients [J].
Clark, DJ ;
Lipworth, BJ .
THORAX, 1997, 52 (01) :55-58
[8]
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients [J].
Clark, DJ ;
Grove, A ;
Cargill, RI ;
Lipworth, BJ .
THORAX, 1996, 51 (03) :262-266
[9]
Use of inhaled corticosteroids and the risk of cataracts [J].
Cumming, RG ;
Mitchell, P ;
Leeder, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (01) :8-14
[10]
Effects of budesonide and fluticasone on 24-hour plasma cortisol - A dose-response [J].
Donnelly, R ;
Williams, KM ;
Baker, AB ;
Badcock, CA ;
Day, RO ;
Seale, JP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (06) :1746-1751